Virpax® Pharmaceuticals Inc., (Nasdaq: VRPX) is a publicly held specialty pharmaceutical company located in Berwyn, PA and is focused on advancing the development and worldwide commercialization of its non-addictive pain and neurological disorder pipeline.
Virpax’s transforming drug-delivery platforms and their targeted drug-releasing capabilities have been developed to enhance compliance and to optimize the efficacy of our non-addictive pain management pipeline and our Central Nervous System (CNS) disorder pipeline.
Virpax’s non-addictive pain management pipeline is being developed in collaboration with the National Institute of Health (NIH) and the Department of Defense (DoD). We anticipate advancing two pain assets into human trials in 2024. Once approved, these pain management alternatives may provide treatment options that help patients achieve better health outcomes.